Menu
← Oncology Approval Tracker
FDA DECISION ·
Breyanzi
lisocabtagene maraleucel · Juno Therapeutics / Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma after two or more prior systemic therapy lines. FDA converted this accelerated indication to traditional approval.
LAMPGEN ANALYSIS
Why it matters
The conversion confirms the regulatory status of the follicular lymphoma indication. Keep the evidence for this use separate from Breyanzi’s other lymphoma indications.
What research teams should watch
Document histology and prior therapy lines, and account for referral, cell collection and treatment-center capacity when discussing access.
PRIMARY RECORDS